Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 1: Interleukin-5 Antagonists - Mepolizumab and Reslizumab
Phase: PHASE1
Conditions: Healthy Subjects, Pharmacokinetics, Pharmacodynamics
Sponsor: Food and Drug Administration (FDA)

Study Title: Pharmacodynamic Biomarkers to Support Biosimilar Development: 
Clinical Study 1 (IL-5 Antagonists – Mepolizumab and Reslizumab) 
 
Document Title: Clinical Study Protocol – Study No. SCR-006 
 
Document Date: 25 June 2020 
 
NCT Number: NCT04183192 

Digitally signed by David Strauss -S 
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 
cn=David Strauss -S, 0.9.2342.19200300.100.1.1=2000507494 
Date: 2020.06.28 21:36:40 -04'00'